Mechanistically, CDKL1 interacts with the transcription factor YBX1, reducing YBX1 binding to the PD-L1 promoter, thereby inhibiting PD-L1 expression, activating CD8+ T cells, and preventing tumor immune escape (21). Here, CD8A is linked to neoplasm.